Captrust Financial Advisors Dynavax Technologies Corp Transaction History

Captrust Financial Advisors

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 15, 2023	SELL	$10.27 - $13.29 $7,076 - $9,156	-689 Reduced 4.73%	13,867 $147,000
Q3 2022 Nov 16, 2022	BUY	$9.93 - $17.44 $41,904 - $73,596	4,220 Added 40.83%	14,556 $152,000
Q2 2022 Aug 23, 2022	SELL	$7.45 - $12.83 $7,956 - $13,702	-1,068 Reduced 9.37%	10,336 $130,000
Q2 2022 Aug 16, 2022	BUY	$7.45 - $12.83 $78,627 - $135,407	10,554 Added 1241.65%	11,404 $144,000
Q1 2022 May 16, 2022	BUY	$9.75 - $14.44 $341 - $505	35 Added 4.29%	850 $9,000
Q3 2021 Nov 16, 2021	BUY	$9.16 - $19.83 $5,486 - $11,878	599 Added 277.31%	815 $16,000
Q1 2021 May 17, 2021	BUY	$4.57 - $11.18 $987 - $2,414	216 New	216 $2,000

257

132M

371K

99.2K

Ticker DVAX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 126,474,000
Market Cap $1.44B
Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.